Chromocell presents pipeline update at Sidoti conference, plans Phase 2a for CC8464

Pelthos Therapeutics Inc.

Phase 1 of CC8464 completed; 6 of 159 subjects (4%) experienced a rash; FDA accepted dose-escalation plan to reduce incidence.
Plans Phase 2a proof-of-concept in idiopathic small fiber neuropathy (~240 patients) and open-label erythromelalgia study (N=10).
Eye pain program: developing a CC8464 eye drop; pre-clinical ophthalmologic safety studies and POC in PRK surgery patients planned.
Sublingual programs: exclusive worldwide license from Benuvia for diclofenac, rizatriptan, ondansetron; 505(b)(2) regulatory pathway.
Company presented at Sidoti Small Cap Conference on March 13, 2024, with CEO Frank Knuettel and CMO Eric Lang.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.